Desonide hydrogel: advances in vehicle technology

References

• Smith EB, Gregory JF, Bartruff JK. Desonide, a potent nonfluorinated topical steroid, vasoconstriction assay and clinical trial. South Med. J.66, 325–329 (1973).
   PubMed Web of Science ®Google Scholar
• Kahanek N, Gelbard C, Hebert A. Desonide: a review of formulations, efficacy and safety. Expert Opin. Investig. Drugs17, 1097–1104 (2008).
   PubMed Web of Science ®Google Scholar
• Phillips B, Sanen F, Leeling J et al. The physical, animal and human pharmacologic and toxicologic properties of desonide, a new, topically active, antiinflammatory steroid. Toxicol. Appl. Pharmacol.20, 522–537 (1971).
   PubMed Web of Science ®Google Scholar
• Lucky AW, Grote, GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic–pituitary–adrenal axis of children with atopic dermatitis. Cutis59, 151–153 (1997).
   PubMed Web of Science ®Google Scholar
• Wong VK, Fuchs B, Lebwohl M. Overview on desonide 0.05%: a clinical safety profile. J. Drugs Dermatol.3(4), 393–397 (2004).
   PubMedGoogle Scholar
• Kircik L, Del Rosso J. A novel hydrogel vehicle formulated for the treatment of atopic dermatitis. J. Drugs Dermatol.6, 718–722 (2007).
   PubMedGoogle Scholar
• Hebert AA, Cook-Bolden FE, Basu S, Calvarese B, Trancik RJ. Safety and efficacy of desonide hydrogel 0.05% in pediatric subjects with atopic dermatitis. J. Drugs Dermatol.6, 175–181 (2007).
   PubMedGoogle Scholar
• Desonate® (desonide) Gel 0.05%. Package insert. SkinMedica, Inc. (2007).
   Google Scholar
• Thalen A, Brattsand R, Andersson PH. Development of glucocorticosteroids with enhanced ratio between topical and systemic effects. Acta Derm. Venereol.151(Suppl.), 11–19 (1989).
   Google Scholar
• Wolverton S. Comprehensive Dermatologic Drug Therapy (2nd Edition). Elsevier, PA, USA (2007).
   Google Scholar
• Stahn C, Lowenberg M, Hommes DW, Buttgereit F. Molecular mechanisms of glucocorticoid action and selective glucocorticoid receptor agonists. Mol. Cell. Endocrinol.275, 71–78 (2007).
   PubMed Web of Science ®Google Scholar
• Ahluwalia A. Topical glucocorticoids and the skin – mechanisms of action: an update. Mediators Inflamm.7, 183–193 (1998).
   PubMed Web of Science ®Google Scholar
• Hebert AA, Cook-Bolden FE, Ford RO, Gotz V. Early relief of atopic dermatitis: symptoms with a novel hydrogel formulation of desonide 0.05% in pediatric subjects. Presented at: 66th Annual Meeting of the American Academy of Dermatology. San Antonio, TX, USA, 1–5 February 2008 (Poster 614).
   Google Scholar
• Data on file. SkinMedica, Inc.
   Google Scholar
• Trookman NS, Rizer,RL Ford R, Trancik RJ. Atopic dermatitis: advantages of a novel hydrogel vehicle. Presented at: 65th Annual Meeting of the American Academy of Dermatology. Washington DC, USA, 2–6 February 2007 (Poster 730).
   Google Scholar
• Brodell RT, O’Brien MJ Jr. Topical corticosteroid-induced acne. Three treatment strategies to break the ‘addiction’ cycle. Postgrad. Med.106, 225–226, 229 (1999).
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Basu S, Calvarese B, Trancik RJ. Effect of desonide hydrogel 0.05% on the hypothalamic–pituitary–adrenal axis in pediatric subjects with moderate to severe atopic dermatitis. Pediatr. Dermatol.24, 289–295 (2007).
   PubMed Web of Science ®Google Scholar
• Foti C, Cassano N, Vena GA. Evaluation of cross-reactivity between budesonide and desonide. Contact Derm.47, 109–110 (2002).
   PubMed Web of Science ®Google Scholar
• Sturtz RP, Rau RC. Contact dermatitis to desonide. Arch. Dermatol.119, 1023 (1983).
   PubMed Web of Science ®Google Scholar
• Rivara G, Tomb RR, Foussereau J. Allergic contact dermatitis from topical corticosteroids. Contact Derm.21, 83–91 (1989).
   PubMed Web of Science ®Google Scholar
• Lucky AW, Grote GD, Williams JL et al. Effect of desonide ointment, 0.05%, on the hypothalamic-pituitary-adrenal axis of children with atopic dermatitis. Cutis59, 151–153 (1997).
   PubMed Web of Science ®Google Scholar
• Lebrun-Vignes B, Legrain V, Amoric J, Taieb A. [Comparative study of efficacy and effect on plasma cortisol levels of micronised desonide cream 0.1 p. 100 versus betamethasone dipropionate cream 0.05 p. 100 In the treatment of childhood atopic dermatitis]. Ann. Dermatol. Venereol.127, 590–595 (2000).
   PubMed Web of Science ®Google Scholar